Banks

A Munich-based banker at UniCredit has made an internal move from MTNs to the syndicate desk, covering SSAs and covered bonds.

DWF has become the first UK law firm to list on the main market London Stock Exchange, after the company priced its £95m IPO at 122p a share on Monday.

KfW sold a tap in sterling on Monday with lead managers maintaining that the choice of an intraday execution was “key” ahead of a vote in UK parliament on prime minister Theresa May’s revised Brexit deal.

Kommunekredit, Kommunalbanken (KBN) and World Bank hit screens for dollar deals on Monday, as bankers said that this week offers a decent window for issuance in the US currency.

Commerzbank and Deutsche Börse have completed of a repo transaction using blockchain technology, opening up the possibility of a secondary market environment operating on distributed ledger.

Medacta, the Swiss maker of artificial human joints, has begun a process to list on the SIX Swiss Exchange before Easter. If it succeeds, it would be the first major company to complete an IPO in Europe this year.

The prospect of a tie-up between Deutsche Bank and Commerzbank has put FIG bankers on red alert as they anticipate a ripple effect of bank consolidation across Europe.

Macquarie Group is strengthening its global macro strategy team, adding FX specialists to be based at both its Hong Kong and London offices.

Nordea managed to raise €1.5bn of seven year funding at 4bp over mid-swaps on Monday — the tightest spread of any covered bond issued this year, other than in Germany. But subscription ratios for core covered bonds are falling and some key investors are lowering their orders.

Barclays is ready to head to Japan with a new bond offering if a series of crucial votes in the UK Parliament this week can help to clarify the next steps in the Brexit process.

Investors have received a note from Helaba saying that a DAX company will market a benchmark Schuldschein (SSD) as early as this week — but only investors signed up to the technology platform VC Trade will be able to bid.

China-based biotechnology firm Mabpharm is looking for the greenlight to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.